Table 2.

Summary of Studies Evaluating HIV-Associated Neurocognitive Disorders (HAND) and other Central Nervous System Disorders

Abstract No. Authors	Location	Sample Size	Prevalence	Correlates
Abstract 154 Heaton et al	United States	1555	53% global neuropsychologic impairment	Lower nadir CD4+ counts, detectable HIV RNA in blood, current antiretrovi- ral therapy use
Abstract 464 Vassallo et al	France	107	69% HAND or neuropsycho- logic deficit	Hepatitis C virus coinfection
Abstract 474 Bonnet et al	France	230	25% mild neurocognitive disorder	Older age, AIDS, active hepatitis B virus disease
Abstract 458 McCutchan et al	United States	145	31% HAND	Diabetes mellitus, higher body mass index and triglycerides, lower high- density lipoprotein cholesterol
Abstract 459 Dulioust et al	France	37	51% HAND	Not cardiovascular risk factors
Abstract 477 Duiculescu et al	Romania	43	60% HAND	Higher HIV RNA in cerebrospinal fluid
Abstract 485 Robertson et al	Various	293	29% neurologic abnormalities
Abstract 920 Ruel et al	Uganda	218	HIV-infected performed worse in most measures
Abstract 155 Everall et al	United States	589	17% typical HIV brain pathol- ogy, 78% at least 1 central nervous system abnormality	Antiretroviral therapy nonuse, lower nadir CD4+ counts, higher HIV RNA levels in blood